Trials / Completed
CompletedNCT00185510
Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis
Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis With Advantan Cream
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Purpose of the study: One bothering feature of atopic dermatitis is its relapsing nature. Hence, it is worthwhile to test modes how to efficiently prevent relapses or at least increase the time until the disease recurs. In order to give recommendations to other patients, this study is to scientifically describe efficacy and safety of a given regimen, namely a maintenance therapy with two days a week Advantan.
Detailed description
The study has initially been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Intendis GmbH, a Bayer HealthCare company, is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylprednisolone Aceponate (Advantan, BAY86-4862) | In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week. |
| DRUG | Placebo | 2 days a week Vehicle (Advabase) |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2006-05-01
- Completion
- 2006-06-01
- First posted
- 2005-09-16
- Last updated
- 2023-06-09
Source: ClinicalTrials.gov record NCT00185510. Inclusion in this directory is not an endorsement.